Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients

Experimental Hematology

Volumn 41, Issue 3, 2013, Pages

  Amaru Calzada, Ariel ^a   Pedrini, Olga ^a   Finazzi, Guido ^a   Leoni, Flavio ^b   Mascagni, Paolo ^b   Introna, Martino ^a   Rambaldi, Alessandro ^a   Golay, Josée ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GIVINOSTAT; HYDROXYUREA; JANUS KINASE 2;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

EID: 84874959699     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.013     Document Type: Article

References (41)

1. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:285-293.
2. Kilpivaara O., Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008, 22:1813-1817.
3. Frederiksen H., Farkas D.K., Christiansen C.F., Hasselbalch H.C., Sorensen H.T. Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study. Blood 2011, 118:6515-6520.
4. Cortelazzo S., Finazzi G., Ruggeri M., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995, 332:1132-1136.
5. Fruchtman S.M., Mack K., Kaplan M.E., Peterson P., Berk P.D., Wasserman L.R. From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997, 34:17-23.
6. Ricksten A., Palmqvist L., Johansson P., Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008, 93:1260-1261.
7. Larsen T.S., Pallisgaard N., de Stricker K., Moller M.B., Hasselbalch H.C. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology 2009, 14:11-15.
8. Antonioli E., Carobbio A., Pieri L., et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica 2010, 95:1435-1438.
9. Spivak J.L., Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011, 11:403-414.
10. Rambaldi A., Dellacasa C.M., Finazzi G., et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150:446-455.
11. Pardanani A., Vannucchi A.M., Passamonti F., Cervantes F., Barbui T., Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011, 25:218-225.
12. Guerini V., Barbui V., Spinelli O., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22:740-747.
13. Amaru Calzada A., Todoerti K., Donadoni L., et al. The HDAC Inhibitor Givinostat Modulates the Hematopoietic Transcription Factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. Exp Hematol 2012, in press.
14. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004, 101:1241-1246.
15. Golay J., Cuppini L., Leoni F., et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007, 21:1892-1900.
16. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003, 2:1273-1284.
17. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002, 13:1-13.
18. Kramer O.H., Knauer S.K., Zimmermann D., Stauber R.H., Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008, 27:732-740.
19. Wang Y., Fiskus W., Chong D.G., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
20. Sparrow R.L., Tippett E. Discrimination of live and early apoptotic mononuclear cells by the fluorescent SYTO 16 vital dye. J Immunol Methods 2005, 305:173-187.
21. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
22. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
23. Simboeck E., Sawicka A., Zupkovitz G., et al. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 2010, 285:41062-41073.
24. Stivala L.A., Cazzalini O., Prosperi E. The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. Curr Cancer Drug Targets 2012, 12:85-96.
25. Ferrandiz N., Caraballo J.M., Albajar M., et al. p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Lett 2010, 292:133-139.
26. Forster K., Obermeier A., Mitina O., et al. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Ann Hematol 2008, 87:183-193.
27. Vrana J.A., Decker R.H., Johnson C.R., et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18:7016-7025.
28. Mahyar-Roemer M., Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001, 20:3387-3398.
29. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
30. Suzuki A., Tsutomi Y., Akahane K., Araki T., Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998, 17:931-939.
31. Cmielova J., Rezacova M. Protein and its function based on a subcellular localization. J Cell Biochem 2011, 112:3502-3506.
32. Koster R., di Pietro A., Timmer-Bosscha H., et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010, 120:3594-3605.
33. Levkau B., Koyama H., Raines E.W., et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998, 1:553-563.
34. Jin Y.H., Yoo K.J., Lee Y.H., Lee S.K. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 2000, 275:30256-30263.
35. Gervais J.L., Seth P., Zhang H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 1998, 273:19207-19212.
36. Rahmani M., Yu C., Reese E., et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 2003, 22:6231-6242.
37. Passamonti F. How I treat polycythemia vera. Blood 2012, 120:275-284.
38. Kiladjian J.J., Chevret S., Dosquet C., Chomienne C., Rain J.D. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011, 29:3907-3913.
39. Barbui T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia 2012, 26:1452-1457.
40. Belt R.J., Haas C.D., Kennedy J., Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 1980, 46:455-462.
41. Rambaldi A., Finazzi G., Vannucchi A.M., et al. A phase II study of HDAC inhibitor Givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy. Blood 2011, 118. Abstract 1748.